ABSTRACT
BACKGROUND: Edema associated with quetiapine has been described in only one case report to date and represents a potentially serious adverse reaction. METHODS: We present a case series of 3 patients who developed bilateral leg edema following initiation of quetiapine. RESULTS: One of these patients had a recurrence of edema with subsequent rechallenge. Another patient developed quetiapine-induced edema following a prior episode of olanzapine-induced edema. All 3 cases present a compelling temporal relationship between the drug challenge and the adverse event. CONCLUSION: Prompt recognition and intervention with discontinuation of the offending agent is important for this potentially serious, seemingly idiosyncratic vascular complication.
Subject(s)
Antipsychotic Agents/adverse effects , Bipolar Disorder/drug therapy , Bipolar Disorder/psychology , Depression/drug therapy , Depression/psychology , Dibenzothiazepines/adverse effects , Edema/chemically induced , Psychomotor Agitation/drug therapy , Adult , Drug Administration Schedule , Female , Humans , Middle Aged , Psychomotor Agitation/psychology , Quetiapine Fumarate , Suicide, Attempted/psychologyABSTRACT
Ephedra extract is used in a number of dietary supplements taken for a variety of purposes including weight loss. Although recent events have led to calls for Ephedra to be removed from the market and the FDA has had over 18,000 adverse event reports, newspaper reports cite only a few instances of clearly associated adverse events associated with Ephedra use. In this communication, we review the literature and present a case report of Ephedra use associated with the onset of psychosis and autonomic hyperactivity after administration of risperidone. We conclude that the behavioral effects of Ephedra are a public health concern.
